Pfizer (NYSE: PFE), for example, is seeing sales of its former $ 13 billion Lipitor stabilize at around $ 1.6 billion annually, and M&A, including its $ 160 billion proposed deal to buy Allergan (NYSE: AGN), is bolstering the likelihood of future revenue growth. (fool.com)
At the centre of Amatil X is AX Ventures, a multimillion dollar corporate venturing program, set up to invest in future revenue growth opportunities outside of Amatil's core - and beyond innovation in beverages which sits within the core business. (ccamatil.com)
Soummo Mukherjee, lead analyst for Oi at Moody's Investors Service, says: «We have affirmed Oi's existing Baa3 rating due to the expected benefits of size and scale in an equity - financed transaction and some benefits of synergies, but more importantly, sharing of best practices to help Oi's future revenue growth path.» (gfmag.com)